High-dose rate brachytherapy in prostate cancer patients--a study on nausea and vomiting
Keats, S.
Urologic Nursing 30(3): 195-202
2010
ISSN/ISBN: 1053-816X PMID: 20648857 Document Number: 640489
High-dose rate brachytherapy (HDRB) is one of many treatments for prostate cancer. Despite a reported 80% to 90% success rate in terms of cure rates, nausea and vomiting have been noted as a significant problem. At St. Vincent's Private Hospital, an incidence of nausea and vomiting was estimated at 67% of patients undergoing HDRB. This study examines the possible causes and risk factors of post-operative nausea and vomiting with this treatment option.
Document emailed within 1 workday
Related Documents
Stromberg, J.S.; Martinez, A.A.; Horwitz, E.M.; Gustafson, G.S.; Gonzalez, J.A.; Spencer, W.F.; Brabbins, D.S.; Dmuchowski, C.F.; Hollander, J.B.; Vicini, F.A. 1997: Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment Cancer Journal from Scientific American 3(6): 346-352Inoue, T.; Inoue, T.; Yoshioka, Y.; Yoshida, K. 2000: High-dose rate interstitial brachytherapy for mobile tongue cancer: Part 3. Comparative study of early mucosal reaction and late tongue atrophy between LDR and HDR Ir-192 interstitial brachytherapy for patients with carcinoma of the mobile tongue Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 296-300
Numbenjapon, T.; Sriswasdi, C.; Mongkonsritragoon, W.; Leelasiri, A.; Prayoonwiwat, W. 2002: Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma Journal of the Medical Association of Thailand 85(11): 1156-1163
Nicolaides, C.; Giannakakis, T.; Skarlos, D.; Athanassiadis, A.; Fountzilas, G.; Damigos, D.; Pavlidis, N. 1998: Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin Journal of Experimental and Clinical Cancer Research: Cr 17(1): 71-75
Pacetti, U.; Veltri, E.; Fattoruso, S.Ileana.Sara.; Cardillo, F.D'Assisi.; Evangelista, S.; Cognetti, F.; Fabi, A. 2013: Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer Anticancer Research 33(4): 1721-1724
Tan, H.S. 1994: Use of high dose rate gammamed brachytherapy in the palliative treatment of gynaecological cancer Annals of the Academy of Medicine Singapore 23(2): 231-234
Kwekkeboom, K.L.; Dendaas, N.R.; Straub, M.; Bradley, K.A. 2009: Patterns of pain and distress during high-dose-rate intracavity brachytherapy for cervical cancer Journal of Supportive Oncology 7(3): 108-114
Petera, J.; Dolezel, M.; Jirousek, Z.; Tucek, L.; Bedrosová, J.; Frgala, T. 2006: High dose rate brachytherapy in the treatment of oral cancer--the preliminary one institution experience Neoplasma 53(3): 232-236
Soumarová, R.; Homola, L.; Stursa, M.; Perková, H. 2006: Acute adverse effects of high dose brachytherapy in combination with external radiotherapy in localized prostate cancer Casopis Lekaru Ceskych 145(1): 43-49
Takácsi-Nagy, Zán.; Varga, János.; Poller, I.; Fodor, János.; Polgár, C.; Petrányi, A.; Major, T.; Németh, Görgy. 2002: Successful treatment of a T1 cancer of the pancreatic head with high dose rate brachytherapy and external radiotherapy Hepato-Gastroenterology 49(45): 844-846
Feng, J. 1994: Care of high dose rate (HDR) brachytherapy in nasopharyngeal carcinoma Zhonghua Hu Li Za Zhi 29(9): 532-534
Osoba, D.; Erlichman, C.; Willan, A.R.; Levitt, M.; Pater, J.L. 1986: Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy Clinical and Investigative Medicine 9(4): 225-231
Righi, D.; Maass, J.; Zanon, E.; Tettoni, S.; Orecchia, R.; Lazzari, R.; Ragona, R.; Gandini, G. 1994: Percutaneous treatment of hilar cholangiocarcinoma completed by high-dose rate brachytherapy. Experience in the first 5 cases La Radiologia Medica 88(1-2): 79-85
Sitathanee, C.; Pairatchvet, V.; Narkwong, L.; Puataweepong, P. 2005: High-dose-rate interstitial brachytherapy in the management of carcinoma of the uterine cervix and other gynecologic malignancies Journal of the Medical Association of Thailand 88(8): 1045-1050
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Tscheikuna, J.; Disayabutr, S.; Kakanaporn, C.; Tuntipumi-Amorn, L.; Chansilpa, Y. 2013: High dose rate endobronchial brachytherapy (HDR-EB) in recurrent benign complex tracheobronchial stenosis: experience in two cases Journal of the Medical Association of Thailand 96(Suppl 2): S252-S256
Dolgin, M.J.; Katz, E.R.; McGinty, K.; Siegel, S.E. 1985: Anticipatory nausea and vomiting in pediatric cancer patients Pediatrics 75(3): 547-552
Boulware, R.J.; Neglia, W.J.; Truesdale, D.W. 1996: Preliminary evaluation of the use of high dose rate brachytherapy in conjunction with external beam radiation and chemotherapy in the definitive management of cervical carcinoma Journal of the South Carolina Medical Association 92(7): 311-315
Aapro, M.S. 1981: Prevention of chemotherapy-induced nausea and vomiting in patients with cancer Arizona Medicine 38(11): 843-845
Johnson, M.H.; Moroney, C.E.; Gay, C.F. 1997: Relieving nausea and vomiting in patients with cancer: a treatment algorithm Oncology Nursing Forum 24(1): 51-57